Icon ArrowBack
Bio Usawa Welcomes Vince Anicetti to the Board of Directors

April 11, 2024: Kigali, Rwanda and San Francisco, USA

Bio Usawa Inc. (BUI) is excited to welcome Vince Anicetti to its Board of Directors. Bringing over four decades of expertise and leadership in the biopharmaceutical industry, Anicetti’s addition signifies a pivotal moment in BUI’s journey towards making high-quality, affordable healthcare accessible across Africa. Ancetti will serve as the Chairman of the Manufacturing Advisory Board for BUI.

As one of its earliest hires, Vince Anicetti had a 30-year career at Genentech, the premier company in the manufacturing of monoclonal antibodies, where he held senior executive roles in Quality, Regulatory Affairs, Product Development, and Operations. He ultimately served as Vice President of Biologics Quality for Genentech and Roche global biologics manufacturing operations. This experience has equipped Anicetti with an unparalleled depth of knowledge in biologics’ quality assurance and global manufacturing oversight. Anicetti subsequently held senior executive roles at Boehringer Ingelheim and later as COO at Coherus Biosciences. Anicetti continues as a strategic advisor with Coherus and sits on advisory boards for Allakos Inc. and Gore. His commitment to education and industry standards shines through his adjunct professorship at the Keck Graduate Institute and his service on the boards of the Parenteral Drug Association and the San Francisco State University Foundation.

Dr. Menghis Bairu, Co-founder and CEO of BUI, remarked, “Our journey towards healthcare equity in Africa is greatly enhanced with Vince Anicetti on board. Vince’s unparalleled experience and leadership in biopharmaceutical quality and regulatory affairs make him an invaluable addition to our board. His vision aligns perfectly with our mission to revolutionize healthcare access across Africa.” 

“It is a privilege to join Bio Usawa and its effort to bring affordable biologic medicines to Africa,” commented Anicetti. “We will use the technological advances of the past four decades to build and operate large-scale, state-of-the-art biologic manufacturing plants in Africa that will enable Bio Usawa to dramatically reduce costs and logistics while ensuring the highest product quality. I look forward to the day when our facilities are on-line and providing lifesaving medicines produced in Africa for patients in Africa and beyond.”

The Bio Usawa team extends a warm welcome to Vince Anicetti, looking forward to his contributions in shaping a healthier future for Africa.

For more details click here: v6_Press_release-Vince_Anicetti.pdf
Other News
African Organization for Research & Trai…

Bio Usawa Inc cofounder grateful to have been a part of the prestigious African Organization for Research & Training in Cancer (APRTIC) Conference, in D…

Nov 2023
Bio Usawa co-founders visiting the Insti…

It was a distinct pleasure to meet with the leadership of the prestigious Institute and tour the facility. Bio Usawa and IPD share a common goal of d…

Nov 2023
Bio Usawa at the 2023 ASH Conference

Humbled and honored to have had the opportunity to discuss Bio Usawa’s vision with highly accomplished hematologists and oncologists at the wel…

Dec 2023
Rwanda Development Board

Dr. Menghis Bairu, co-founder and CEO of Biousawa Biotechnology Ltd in a meeting with Mr. Francis Gatare, CEO, #RwandaDevelopment Board shared the compa…

Feb 2024
TWIN group delegation to visit Dr Sabin …

It was such an honor for our TWIN group delegation to visit Dr Sabin Nsanzimana, Minister of Health, #Rwanda. I shared briefly our Rwanda based #BioUsaw…

Feb 2024
Africa, the Oldest and Newest Frontier

Most people know Oliver Wendell Holmes Sr., the father of the Supreme Court Justice Oliver Wendell Holmes Jr., as a poet and a writer. Along with Lon…

Feb 2024
Bio Usawa Announces the Establishment of…

A major step towards providing safe, effective and affordable biologics in Africa and beyond.
KIGALI, RWANDA AND SAN FRANCISCO, CALIFORNIA&mdash…

Feb 2024
Monoclonal Antibodies for Malaria | NEJM

Monoclonal Antibodies for Malaria

Malaria is a devastating disease. It was the cause of 627,000 deaths worldwide in 2020, and malaria-related…

Feb 2024
Bio Usawa Inc. Joins African Diaspora Ne…

BIO USAWA INC. is pleased to announce its participation in the prestigious African Diaspora Network Forum, scheduled to occur from March 20th to 22nd 20…

Mar 2024
Bio Usawa Inc. Lauds United States' Comm…

In a landmark move for global healthcare, Bio Usawa Inc., a pioneering African manufacturer of monoclonal antibodies (MAB), commends the United States g…

Apr 2024
Bio Usawa Inc. Visits Bio Vax Institute …

Bio Usawa Inc. team led by Dr. Menghis Bairu, Co-founder, CEO and President, John Hautman Bio Usawa Chief Legal officer and Bio Usawa Consultant Carolyn…

Feb 2024
Democratizing Access To Biologics In Afr…

“Our mission at Bio Usawa is to ensure that no African patient is denied access to essential therapies due to financial constraints,” stated Dr. Bairu. …

Apr 2024
Bridging The Gap: Why Africa Must Embrac…

In the race towards Universal Health Coverage (UHC) in Africa, the integration of biosimilars, particularly monoclonal antibodies (MABs), stands out as …

Apr 2024
Unlocking Healthcare Value Chains And Dr…

Attending the upcoming Lagos, Nigeria May 7-9, 2024 Industry Engagement Forum themed “Unlocking Healthcare Value Chains and Driving Investment through P…

May 2024
Opinion: Envisioning Africa’s Renaissanc…

The African diaspora's role in the continent's socioeconomic transformation can no longer be overlooked. As we delve deeper into the 21st century, it be…

May 2024
Bio Usawa Welcomes Dr. Raj Shankar Ghos…

Bio Usawa Inc. (BUI) is excited to welcome Raj Shankar Ghosh as Chief Innovation and Strategy Officer to its leadership team. With over three and a half…

Jun 2024
Opinion: Charting A Course For Equitable…

As the global population ages, Alzheimer's disease (AD) emerges as a chief concern for health systems and increasingly as a mirror reflecting the deep i…

Jun 2024